Wednesday, July 8, 2026

Drug profile · INN

dexlansoprazole

dexlansoprazole (DEXLANSOPRAZOLE) is a potassium-transporting atpase inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 15
Pipeline programs 22
News articles 0
Drug details — dexlansoprazole
US status
approved
Class
Route
ORAL
Patents
15
Programs
22
Data quality
0.89

Quick answer

dexlansoprazole (DEXLANSOPRAZOLE) is a potassium-transporting atpase inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN dexlansoprazole
Brand DEXLANSOPRAZOLE
Mechanism Potassium-transporting ATPase inhibitor
Target Potassium-transporting ATPase
Route ORAL
Formulation TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
Originator Takeda

Mechanism of action

Potassium-transporting ATPase inhibitor

Primary target: Potassium-transporting ATPase

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Dexlansoprazole Phase 3 · Takeda · Gastroesophageal Reflux
  2. Dexlansoprazole Phase 3 · Takeda · Heartburn
  3. Dexlansoprazole Phase 3 · Takeda · Erosive Esophagitis
  4. Dexlansoprazole MR Phase 3 · Takeda · Esophagitis, Reflux
  5. Dexlansoprazole MR Phase 3 · Takeda · Gastroesophageal Reflux Disease
  6. Dexlansoprazole MR QD Phase 3 · Takeda · Gastroesophageal Reflux
  7. Dexlansoprazole Phase 2 · Takeda · Gastroesophageal Reflux Disease (GERD)
  8. Dexlansoprazole Phase 2 · Takeda · Barrett's Esophagus

Related & competitor drugs

  1. esomeprazole magnesium Potassium-transporting ATPase inhibitor
  2. lansoprazole Potassium-transporting ATPase inhibitor
  3. omeprazole Potassium-transporting ATPase inhibitor
  4. pantoprazole sodium Potassium-transporting ATPase inhibitor
  5. rabeprazole sodium Potassium-transporting ATPase inhibitor
  6. vonoprazan fumarate Potassium-transporting ATPase inhibitor
  1. US 9241910

    Orally-disintegrating solid preparation

    Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 9238029

    Multiple PPI dosage form

    Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 9233103

    Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 9114085

    Modified release pharmaceutical compositions of dexlansoprazole

    Expires Mon Aug 20 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 9011926

    Method for producing granules

    Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 8871273

    Method for producing granules

    Expires Mon Oct 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 8758818

    Oral tablet compositions of dexlansoprazole

    Expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 8753682

    Dual release oral tablet compositions of dexlansoprazole

    Expires Mon Jun 12 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 8741345

    Modified release pharmaceutical compositions of dexlansoprazole

    Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 8563035

    Oral tablet compositions of dexlansoprazole

    Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 8563034

    Dual release oral tablet compositions of dexlansoprazole

    Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 8461187

    Multiple PPI dosage form

    Expires Mon Jun 06 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 8173158

    Methods of treating gastrointestinal disorders independent of the intake of food

    Expires Mon May 03 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 8105626

    Granules containing acid-unstable chemical in large amount

    Expires Mon Jan 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 7790755

    Controlled release preparation

    Expires Mon Sep 02 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is dexlansoprazole?

dexlansoprazole (DEXLANSOPRAZOLE) is a potassium-transporting atpase inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for dexlansoprazole?

DEXLANSOPRAZOLE is a marketed brand name for dexlansoprazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of dexlansoprazole?

dexlansoprazole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.